A citation-based method for searching scientific literature

Lisa C Brown, Joseph D Stanton, Kanika Bharthi, Abdullah Al Maruf, Daniel J Müller, Chad A Bousman. Clin Pharmacol Ther 2022
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel.
Chad Bousman, Abdullah Al Maruf, Daniel J Müller. Curr Opin Psychiatry 2019
40
50




Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Masato Saito, Norio Yasui-Furukori, Tsukasa Uno, Takenori Takahata, Kazunobu Sugawara, Akihiro Munakata, Tomonori Tateishi. Br J Clin Pharmacol 2005
37
50

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.
Kelly E Caudle, Katrin Sangkuhl, Michelle Whirl-Carrillo, Jesse J Swen, Cyrine E Haidar, Teri E Klein, Roseann S Gammal, Mary V Relling, Stuart A Scott, Daniel L Hertz,[...]. Clin Transl Sci 2020
213
50

Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
Filip Milosavljevic, Nikola Bukvic, Zorana Pavlovic, Cedo Miljevic, Vesna Pešic, Espen Molden, Magnus Ingelman-Sundberg, Stefan Leucht, Marin M Jukic. JAMA Psychiatry 2021
34
50

Opportunities for pharmacists to integrate pharmacogenomics into clinical practice.
Yan-Ting Wang, Man Yee Merl, Jun Yang, Zhi-Xiang Zhu, Guo-Hui Li. Pharmacogenomics J 2020
16
50

Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
Chad A Bousman, Katarina Arandjelovic, Serafino G Mancuso, Harris A Eyre, Boadie W Dunlop. Pharmacogenomics 2019
85
50


Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
J K Hicks, K Sangkuhl, J J Swen, V L Ellingrod, D J Müller, K Shimoda, J R Bishop, E D Kharasch, T C Skaar, A Gaedigk,[...]. Clin Pharmacol Ther 2017
290
50

A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013.
David A Mrazek, John C Hornberger, C Anthony Altar, Irina Degtiar. Psychiatr Serv 2014
291
50

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
B A Hamelin, A Bouayad, J Méthot, J Jobin, P Desgagnés, P Poirier, J Allaire, J Dumesnil, J Turgeon. Clin Pharmacol Ther 2000
108
50

Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
David W Oslin, Kevin G Lynch, Mei-Chiung Shih, Erin P Ingram, Laura O Wray, Sara R Chapman, Henry R Kranzler, Joel Gelernter, Jeffrey M Pyne, Annjanette Stone,[...]. JAMA 2022
10
50

Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility.
Paul Bradley, Michael Shiekh, Vishaal Mehra, Keith Vrbicky, Stacey Layle, Marilyn C Olson, Alejandra Maciel, Ali Cullors, Jorge A Garces, Andrew A Lukowiak. J Psychiatr Res 2018
91
50

Use of Pharmacogenetic Drugs by the Dutch Population.
Mohammad A Alshabeeb, Vera H M Deneer, Amjad Khan, Folkert W Asselbergs. Front Genet 2019
18
50

Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4.
K Venkatakrishnan, D J Greenblatt, L L von Moltke, J Schmider, J S Harmatz, R I Shader. J Clin Pharmacol 1998
134
50





Pharmacogenetics: from bench to byte--an update of guidelines.
J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw,[...]. Clin Pharmacol Ther 2011
651
50

Polypharmacy in psychiatry: a review.
Sanjay Kukreja, Gurvinder Kalra, Nilesh Shah, Amresh Shrivastava. Mens Sana Monogr 2013
71
50

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.
Hui-Yan Shi, Jin Yan, Wen-Hui Zhu, Guo-Ping Yang, Zhi-Rong Tan, Wei-Hua Wu, Gan Zhou, Xiao-Ping Chen, Dong-Sheng Ouyang. Eur J Clin Pharmacol 2010
39
50

Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.
A M Harmsze, J W van Werkum, P C Souverein, N J Breet, H J Bouman, C M Hackeng, H J T Ruven, J M ten Berg, O H Klungel, A de Boer,[...]. J Thromb Haemost 2011
33
50

Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.
John F Greden, Sagar V Parikh, Anthony J Rothschild, Michael E Thase, Boadie W Dunlop, Charles DeBattista, Charles R Conway, Brent P Forester, Francis M Mondimore, Richard C Shelton,[...]. J Psychiatr Res 2019
122
50

Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.
Marin M Jukić, Tore Haslemo, Espen Molden, Magnus Ingelman-Sundberg. Am J Psychiatry 2018
86
50

Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Thibaud Damy, Françoise Pousset, Henri Caplain, Jean-Sébastien Hulot, Philippe Lechat. Fundam Clin Pharmacol 2004
54
50

Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Mary V Relling, Matthias Schwab, Michelle Whirl-Carrillo, Guilherme Suarez-Kurtz, Ching-Hon Pui, Charles M Stein, Ann M Moyer, William E Evans, Teri E Klein, Federico Guillermo Antillon-Klussmann,[...]. Clin Pharmacol Ther 2019
272
50

Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample.
Carin A T C Lunenburg, Janne P Thirstrup, Jonas Bybjerg-Grauholm, Marie Bækvad-Hansen, David M Hougaard, Merete Nordentoft, Thomas Werge, Anders D Børglum, Ole Mors, Preben B Mortensen,[...]. Transl Psychiatry 2021
7
50

A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram.
Line Skute Bråten, Tore Haslemo, Marin M Jukic, Maxim Ivanov, Magnus Ingelman-Sundberg, Espen Molden, Marianne Kristiansen Kringen. Clin Pharmacol Ther 2021
16
50

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
J A Johnson, L Gong, M Whirl-Carrillo, B F Gage, S A Scott, C M Stein, J L Anderson, S E Kimmel, M T M Lee, M Pirmohamed,[...]. Clin Pharmacol Ther 2011
438
50


Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial.
Céline K Stäuble, Markus L Lampert, Samuel Allemann, Martin Hatzinger, Kurt E Hersberger, Henriette E Meyer Zu Schwabedissen, Christian Imboden, Thorsten Mikoteit. Trials 2021
4
50

Contribution of common genetic variants to antidepressant response.
Katherine E Tansey, Michel Guipponi, Xiaolan Hu, Enrico Domenici, Glyn Lewis, Alain Malafosse, Jens R Wendland, Cathryn M Lewis, Peter McGuffin, Rudolf Uher. Biol Psychiatry 2013
130
50

ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.
Alan F Schatzberg, Charles DeBattista, Laura C Lazzeroni, Amit Etkin, Greer M Murphy, Leanne M Williams. Am J Psychiatry 2015
50
50

CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
Li Zhu, Roger J Brüggemann, Jonathan Uy, Angela Colbers, Matthew W Hruska, Ellen Chung, Karen Sims, Blisse Vakkalagadda, Xiaohui Xu, Ron H N van Schaik,[...]. J Clin Pharmacol 2017
21
50

Drug-drug-gene interactions and adverse drug reactions.
Mustafa Adnan Malki, Ewan Robert Pearson. Pharmacogenomics J 2020
46
50

Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
Reka Varnai, Istvan Szabo, Greta Tarlos, Laszlo Jozsef Szentpeteri, Attila Sik, Sandor Balogh, Csilla Sipeky. Pharmacogenomics J 2020
5
50


Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
Víctor Pérez, Ariana Salavert, Jordi Espadaler, Miquel Tuson, Jerónimo Saiz-Ruiz, Cristina Sáez-Navarro, Julio Bobes, Enrique Baca-García, Eduard Vieta, José M Olivares,[...]. BMC Psychiatry 2017
105
50

Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting.
Daniel K Hall-Flavin, Joel G Winner, Josiah D Allen, Joseph M Carhart, Brian Proctor, Karen A Snyder, Maureen S Drews, Linda L Eisterhold, Jennifer Geske, David A Mrazek. Pharmacogenet Genomics 2013
131
50

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.
C Hiemke, N Bergemann, H W Clement, A Conca, J Deckert, K Domschke, G Eckermann, K Egberts, M Gerlach, C Greiner,[...]. Pharmacopsychiatry 2018
438
50


Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Kelly E Caudle, Henry M Dunnenberger, Robert R Freimuth, Josh F Peterson, Jonathan D Burlison, Michelle Whirl-Carrillo, Stuart A Scott, Heidi L Rehm, Marc S Williams, Teri E Klein,[...]. Genet Med 2017
263
50

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Norio Yasui-Furukori, Masato Saito, Tsukasa Uno, Takenori Takahata, Kazunobu Sugawara, Tomonori Tateishi. J Clin Pharmacol 2004
44
50

Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Tsukasa Uno, Mikiko Shimizu, Norio Yasui-Furukori, Kazunobu Sugawara, Tomonori Tateishi. Br J Clin Pharmacol 2006
27
50

Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder.
Gualberto Ruaño, Bonnie L Szarek, David Villagra, Krystyna Gorowski, Mohan Kocherla, Richard L Seip, John W Goethe, Harold I Schwartz. Biomark Med 2013
32
50

Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
Joo-Youn Cho, Kyung-Sang Yu, In-Jin Jang, Byung-Hwan Yang, Sang-Goo Shin, Dong-Seok Yim. Br J Clin Pharmacol 2002
36
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.